Related Experiment Video
Updated: Aug 17, 2026

Phenotypic Profiling of MPTP-Induced Parkinsonian-like Behavioral Phenotypes in Zebrafish Larvae Based on Behavioral Experiment
Published on: May 15, 2026
Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism
Weihong Feng1, Huailing Wei, Geng Tao Liu
1Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing, China.
Abstract:
FLZ is a synthetic new derivative of squamosamide. Pharmacological study found that FLZ given orally improved the abnormal behavior caused by the functional disturbance of dopaminergic and cholinergic neurons in mice. FLZ significantly increased the content of dopamine and its metabolites in striatum in MPTP model mice. FLZ also remarkably protected dopaminergic PC-12 cells against dopamine and MPP+ induced injury and apoptosis in vitro. The compound inhibited the formation of dopamine-melanin and protein polymers. Additionally, FLZ inhibited cytochrome-c release from mitochondria and caspase-3 activation by dopamine in PC-12 cells. The above results suggest that compound FLZ possesses anti-PD activity through neuroprotection.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model